Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

2022-11-07

小分子药物抗体免疫疗法

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that abstracts featuring data from its oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston and virtually.

'We look forward to presenting data at the SITC Annual Meeting from our immuno-oncology pipeline, including our oral PD-L1 program, as we make progress toward our goal of identifying new solutions for patients with cancer who need additional options.'

“We are proud of the progress being made across our earlier-stage clinical programs, spanning small molecules, monoclonal and bispecific antibodies,” said Lance Leopold, M.D., Group Vice President, Clinical Development Hematology and Oncology at Incyte. “We look forward to presenting data at the SITC Annual Meeting from our immuno-oncology pipeline, including our oral PD-L1 program, as we make progress toward our goal of identifying new solutions for patients with cancer who need additional options.”

Key abstracts include:

Poster Presentations

All accepted odd-numbered posters are available from 9:00 a.m. – 9:00 p.m. EST on Thursday, November 10. All accepted even-numbered posters are available Friday, November 11, from 9:00 a.m.–8:30 p.m. EST.

INCB099280 (PD-L1)

A Phase 1 Study Exploring the Safety and Tolerability of the PD-L1 Small Molecule Inhibitor INCB099280 in Patients with Select Advanced Solid Tumors (Abstract #734)

INCB099318 (PD-L1)

A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor PD-L1 Inhibitor, INCB099318, in Patients with Select Advanced Solid Tumors (Abstract #662)

INCB086550 (PD-L1)

A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor PD-L1 Inhibitor, INCB086550, in Patients with Select Advanced Tumors (Abstract #774)

INCA32459 (LAG3xPD-1)

Phase 1 First-in-Human, Open-Label, Multicenter Study of INCA32459, a Bispecific Anti–PD1 and Anti–LAG-3 Antibody, in Patients with Select Advanced Malignancies (Abstract #723)

A Human Bispecific Antibody Targeting LAG-3 and PD-1 (INCA32459) Potently Activates Exhausted T Cells (Abstract #1210)

INCAGN01876 (GITR)

A Phase 2, Open-Label, Multicenter Study of INCAGN01876 (anti-GITR agonist GITR agonist) in Combination with Retifanlimab (anti–PD-1) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Abstract #677)

Bispecific Antibody Research

Comparison of Four in Vitro Cytotoxicity Assays for Assessing the Potency of Bispecific Antibodies Redirecting T Cells to Kill Tumor Target Cells (Abstract #1199)

More information regarding the congress is available on the SITC website: https://www.sitcancer.org/2022/home. The virtual meeting platform will be available following the conclusion of the meeting for registered attendees until Monday, Jan. 9, 2023.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions and Incyte’s goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; the effects of the COVID-19 pandemic and measures to address the pandemic on Incyte and its partners’ clinical trials, supply chain, other third-party providers and development and discovery operations; determinations made by the U.S. FDA and other regulatory authorities outside of the United States; the efficacy or safety of Incyte and its partners’ products; the acceptance of Incyte and its partners’ products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended September 30, 2022. Incyte disclaims any intent or obligation to update these forward-looking statements.